vs
Side-by-side financial comparison of Agilent Technologies (A) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Agilent Technologies is the larger business by last-quarter revenue ($1.8B vs $493.8M, roughly 3.6× Pediatrix Medical Group, Inc.). Agilent Technologies runs the higher net margin — 17.0% vs 6.8%, a 10.1% gap on every dollar of revenue. On growth, Agilent Technologies posted the faster year-over-year revenue change (7.0% vs -1.7%). Over the past eight quarters, Agilent Technologies's revenue compounded faster (6.9% CAGR vs -0.1%).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emissi...
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
A vs MD — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $493.8M |
| Net Profit | $305.0M | $33.7M |
| Gross Margin | 52.6% | — |
| Operating Margin | 19.6% | 9.9% |
| Net Margin | 17.0% | 6.8% |
| Revenue YoY | 7.0% | -1.7% |
| Net Profit YoY | -4.1% | 10.5% |
| EPS (diluted) | $1.07 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $493.8M | ||
| Q3 25 | $1.7B | $492.9M | ||
| Q2 25 | $1.7B | $468.8M | ||
| Q1 25 | $1.7B | $458.4M | ||
| Q4 24 | $1.7B | $502.4M | ||
| Q3 24 | $1.6B | $511.2M | ||
| Q2 24 | $1.6B | $504.3M |
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $33.7M | ||
| Q3 25 | $336.0M | $71.7M | ||
| Q2 25 | $215.0M | $39.3M | ||
| Q1 25 | $318.0M | $20.7M | ||
| Q4 24 | $351.0M | $30.5M | ||
| Q3 24 | $282.0M | $19.4M | ||
| Q2 24 | $308.0M | $-153.0M |
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | — | ||
| Q3 25 | 51.1% | — | ||
| Q2 25 | 51.9% | — | ||
| Q1 25 | 53.5% | — | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 54.4% | — |
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | 9.9% | ||
| Q3 25 | 20.7% | 13.8% | ||
| Q2 25 | 18.0% | 12.8% | ||
| Q1 25 | 22.4% | 7.0% | ||
| Q4 24 | 24.0% | 7.8% | ||
| Q3 24 | 21.1% | 6.6% | ||
| Q2 24 | 23.1% | -31.3% |
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | 6.8% | ||
| Q3 25 | 19.3% | 14.5% | ||
| Q2 25 | 12.9% | 8.4% | ||
| Q1 25 | 18.9% | 4.5% | ||
| Q4 24 | 20.6% | 6.1% | ||
| Q3 24 | 17.9% | 3.8% | ||
| Q2 24 | 19.6% | -30.3% |
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $0.40 | ||
| Q3 25 | $1.18 | $0.84 | ||
| Q2 25 | $0.75 | $0.46 | ||
| Q1 25 | $1.11 | $0.24 | ||
| Q4 24 | $1.23 | $0.37 | ||
| Q3 24 | $0.97 | $0.23 | ||
| Q2 24 | $1.05 | $-1.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.8B | $375.2M |
| Total DebtLower is stronger | $3.0B | $570.5M |
| Stockholders' EquityBook value | $6.9B | $865.9M |
| Total Assets | $12.8B | $2.2B |
| Debt / EquityLower = less leverage | 0.44× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $375.2M | ||
| Q3 25 | $1.5B | $340.1M | ||
| Q2 25 | $1.5B | $224.7M | ||
| Q1 25 | $1.5B | $99.0M | ||
| Q4 24 | $1.3B | $229.9M | ||
| Q3 24 | $1.8B | $103.8M | ||
| Q2 24 | $1.7B | $19.4M |
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $570.5M | ||
| Q3 25 | $3.4B | $577.2M | ||
| Q2 25 | $3.3B | $583.9M | ||
| Q1 25 | $3.3B | $590.5M | ||
| Q4 24 | $3.3B | $597.1M | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.1B | — |
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $865.9M | ||
| Q3 25 | $6.4B | $890.7M | ||
| Q2 25 | $6.1B | $833.8M | ||
| Q1 25 | $6.0B | $789.2M | ||
| Q4 24 | $5.9B | $764.9M | ||
| Q3 24 | $5.9B | $732.5M | ||
| Q2 24 | $6.2B | $706.5M |
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $2.2B | ||
| Q3 25 | $12.2B | $2.2B | ||
| Q2 25 | $12.2B | $2.1B | ||
| Q1 25 | $11.9B | $2.0B | ||
| Q4 24 | $11.8B | $2.2B | ||
| Q3 24 | $11.0B | $2.1B | ||
| Q2 24 | $10.9B | $2.0B |
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 0.66× | ||
| Q3 25 | 0.53× | 0.65× | ||
| Q2 25 | 0.55× | 0.70× | ||
| Q1 25 | 0.56× | 0.75× | ||
| Q4 24 | 0.57× | 0.78× | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | 0.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $268.0M | $114.1M |
| Free Cash FlowOCF − Capex | $175.0M | — |
| FCF MarginFCF / Revenue | 9.7% | — |
| Capex IntensityCapex / Revenue | 5.2% | — |
| Cash ConversionOCF / Net Profit | 0.88× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $993.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $114.1M | ||
| Q3 25 | $362.0M | $137.3M | ||
| Q2 25 | $221.0M | $137.2M | ||
| Q1 25 | $431.0M | $-117.5M | ||
| Q4 24 | $481.0M | $133.0M | ||
| Q3 24 | $452.0M | $91.8M | ||
| Q2 24 | $333.0M | $107.0M |
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $107.0M | — | ||
| Q1 25 | $334.0M | — | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | — |
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | — |
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 6.5% | — |
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | 3.39× | ||
| Q3 25 | 1.08× | 1.91× | ||
| Q2 25 | 1.03× | 3.49× | ||
| Q1 25 | 1.36× | -5.66× | ||
| Q4 24 | 1.37× | 4.36× | ||
| Q3 24 | 1.60× | 4.72× | ||
| Q2 24 | 1.08× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
